enzastaurin + bevacizumab + Enzyme-inducing antiepileptic drugs (EIAED) + Non-enzyme inducing antiepileptic drugs (NEIAED)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Glioblastoma
Conditions
Recurrent Glioblastoma
Trial Timeline
Nov 1, 2007 → Oct 1, 2013
NCT ID
NCT00586508About enzastaurin + bevacizumab + Enzyme-inducing antiepileptic drugs (EIAED) + Non-enzyme inducing antiepileptic drugs (NEIAED)
enzastaurin + bevacizumab + Enzyme-inducing antiepileptic drugs (EIAED) + Non-enzyme inducing antiepileptic drugs (NEIAED) is a phase 2 stage product being developed by Eli Lilly for Recurrent Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00586508. Target conditions include Recurrent Glioblastoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00586508 | Phase 2 | Completed |
Competing Products
20 competing products in Recurrent Glioblastoma